In addition, tissue-specific highly expressed eRNAs, such as CCAT1 in colorectal cancer and androgen receptor (AR)-induced Kallikrein-related peptidase 3 (KLK3) eRNA (KLK3e) in prostate cancer, are considered new targets for treating various cancers14,48,49. This evidence concerns the gene AR and prostate cancer.